Dr. Paul is currently the Chief Executive Officer and Chairman of the Board for Karuna Pharmaceuticals and the Venture Partner at Third Rock Ventures. He was formerly the Chief Executive Officer of Voyager Therapeutics and the Founding Director of the Helen and Robert Appel Alzheimer’s Disease Research Institute and the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases as well as a DeWitt Senior Scholar and Professor of Neuroscience (Brain and Mind Research Institute), Psychiatry and Pharmacology at Weill Cornell Medical College. Dr. Paul was also formerly the Executive Vice President of Science and Technology and President of the Lilly Research Laboratories (LRL) of Eli Lilly and Company, overseeing the development of several of Lilly’s largest products including Zyprexa® and Cymbalta®. Prior to assuming his position at Lilly and Weill Cornell Medical College, Dr. Paul served as Scientific Director of the National Institute of Mental Health (NIMH/NIH) in Bethesda, Maryland.
Current role